TrueBinding
TrueBinding, Inc. is a clinical-stage biotherapeutic company founded in 2016 and headquartered at 4701 Patrick Henry Drive, Santa Clara, California. It develops humanized monoclonal antibodies against Galectin-3 to resolve chronic inflammation ("inflammaging"), led by TB006, which has completed Phase 1b/2a work in Alzheimer's disease and holds an FDA IND clearance for a Phase 2A trial in Parkinson's disease, with additional research programs across ALS, glioblastoma, autism spectrum, stroke, metabolic disease and oncology. Alongside its own pipeline the company sells contract development and manufacturing (CDMO) services from its Santa Clara facility - antibody discovery, cell-line and process development, cGMP monoclonal antibody and media/buffer manufacturing, vivarium and toxicology studies, histology and imaging, clinical drug product logistics, and cGMP training and audit preparation. TrueBinding ships no software product and publishes no public API, SDK, developer portal or machine-readable API contract; its web presence is a Squarespace marketing and patient-access site.
TrueBinding is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Pharmaceuticals, Life Sciences, and Clinical Trials.
TrueBinding’s developer surface includes support, engineering blog, and 5 more developer resources.
Kin Score
Security Posture 1
Authentication, domain security, vulnerability disclosure, and trust-center signals.
Resources
Agent Surfaces 1
MCP servers, agent skills, and machine-readable catalogs
Access & Security 1
Authentication, authorization, and security posture
Operate 1
Status, limits, changes, and where to get help
Commercial 2
Pricing, plans, and the legal terms of use
Company 2
The organization behind the API
Source (apis.yml)
Work with this as data
Every provider here is available over the APIs.io API and to AI agents over MCP.